Brokers Set Expectations for Achillion Pharmaceuticals, Inc.’s Q4 2018 Earnings (ACHN)
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) – Stock analysts at William Blair cut their Q4 2018 EPS estimates for Achillion Pharmaceuticals in a research note issued to investors on Wednesday, November 7th. William Blair analyst Y. Xu now forecasts that the biopharmaceutical company will earn ($0.15) per share for the quarter, down from their previous forecast of ($0.14). William Blair also issued estimates for Achillion Pharmaceuticals’ Q1 2019 earnings at ($0.16) EPS, Q2 2019 earnings at ($0.17) EPS, Q3 2019 earnings at ($0.18) EPS, Q4 2019 earnings at ($0.20) EPS, FY2019 earnings at ($0.52) EPS and FY2020 earnings at ($0.71) EPS.
Separately, BidaskClub lowered shares of Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, October 12th. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $4.38.
Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.02.
Several large investors have recently bought and sold shares of ACHN. UBS Group AG boosted its position in shares of Achillion Pharmaceuticals by 213.6% during the 1st quarter. UBS Group AG now owns 305,137 shares of the biopharmaceutical company’s stock valued at $1,132,000 after purchasing an additional 207,824 shares in the last quarter. California State Teachers Retirement System boosted its position in shares of Achillion Pharmaceuticals by 11.9% during the 1st quarter. California State Teachers Retirement System now owns 206,482 shares of the biopharmaceutical company’s stock valued at $766,000 after purchasing an additional 22,017 shares in the last quarter. Acadian Asset Management LLC bought a new position in shares of Achillion Pharmaceuticals during the 2nd quarter valued at about $135,000. Spark Investment Management LLC boosted its position in shares of Achillion Pharmaceuticals by 95.3% during the 2nd quarter. Spark Investment Management LLC now owns 195,900 shares of the biopharmaceutical company’s stock valued at $554,000 after purchasing an additional 95,600 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new position in shares of Achillion Pharmaceuticals during the 2nd quarter valued at about $689,000. Institutional investors own 79.27% of the company’s stock.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.
Featured Story: Understanding Average Daily Trade Volume
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.